Literature DB >> 1309440

Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines.

K Stromberg1, T J Collins, A W Gordon, C L Jackson, G R Johnson.   

Abstract

The potential of transforming growth factor-alpha (TGF-alpha) to function as an autocrine growth factor was evaluated in numerous ovarian carcinoma cell lines. All 17 lines which were examined expressed the epidermal growth factor receptor and 16 cell lines, in addition, concomitantly secreted TGF-alpha. Radioimmunoassay of processed serum-free-conditioned medium indicated TGF-alpha concentrations ranging from 16 to 197 pg/ml, or 1.5 to 95 ng/10(8) cells. 125I-TGF-alpha bound to a single class of high-affinity-binding sites on the surface of the cells. The dissociation constant for the 125I-TGF-alpha/epidermal growth factor receptor complex ranged from 0.21 to 5.3 nM with receptor numbers from 3,500 to 96,000/cell, depending upon the cell line. The growth of 8 ovarian cell lines was stimulated in a dose-dependent manner when grown in the presence of exogenous TGF-alpha. Growth in 4 of 5 cell lines capable of serum-free propagation was inhibited from 28 to 56% when cultured in medium containing a TGF-alpha-neutralizing monoclonal antibody. These results support the view that TGF-alpha is an autocrine growth factor for cell lines derived from ovarian cancers of epithelial origin and suggest a potential role for TGF-alpha in the pathogenesis or progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309440

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib.

Authors:  Rexxi D Prasasya; Kang Z Vang; Pamela K Kreeger
Journal:  Biotechnol Bioeng       Date:  2011-08-23       Impact factor: 4.530

2.  A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification.

Authors:  B L King; A Lichtenstein; J Berenson; B M Kacinski
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

Review 3.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

4.  Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family.

Authors:  H Toyoda; T Komurasaki; D Uchida; S Morimoto
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

5.  Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion.

Authors:  Song Ling Poon; Gareth T Hammond; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2009-07-16

6.  Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Authors:  Jason A Wilken; Kristy T Webster; Nita J Maihle
Journal:  J Ovarian Res       Date:  2010-03-27       Impact factor: 4.234

7.  Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells.

Authors:  J Hofmann; B Wegmann; R Hackenberg; R Kunzmann; K D Schulz; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Augmentation of 5-fluorouracil cytotoxicity by epidermal growth factor in a newly established human signet-ring cell carcinoma of the stomach in culture.

Authors:  K Aizawa; I Muto; S Suzuki; N Tanaka; H Yabusaki; S Tanaka; N Katayanagi; T Suzuki; O Tanaka; T Muto
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

9.  Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.

Authors:  Yuanda Song; Palmer Wilkins; Wenhui Hu; Karnam S Murthy; Jing Chen; Zendra Lee; Regina Oyesanya; Jinhua Wu; Suzanne E Barbour; Xianjun Fang
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

10.  Absence of constitutive EGF receptor activation in ovarian cancer cell lines.

Authors:  C Ottensmeier; L Swanson; T Strobel; B Druker; J Niloff; S A Cannistra
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.